Unger, J. M., Griffin, K., Donaldson, G. W., Baranowski, K. M., Good, M. J., Reburiano, E., . . . Moinpour, C. M. (2018). Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes.
Citação norma ChicagoUnger, Joseph M., et al. "Patient-reported Outcomes for Patients With Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel and Atrasentan Versus Docetaxel and Placebo in a Randomized Phase III Clinical Trial (SWOG S0421)." J Patient Rep Outcomes 2018.
Citação norma MLAUnger, Joseph M., et al. "Patient-reported Outcomes for Patients With Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel and Atrasentan Versus Docetaxel and Placebo in a Randomized Phase III Clinical Trial (SWOG S0421)." J Patient Rep Outcomes 2018.